Champions Oncology Reports 8.8% Revenue Growth to $15.2 Million with Net Loss of $426,000

Champions Oncology, Inc. reported its financial results for the quarter ending July 31, 2026, revealing a revenue of $15.2 million, an increase of 8.8% from $14.0 million in the same period last year. The growth in revenue was primarily driven by a rise in pharmacology services, which accounted for $14.2 million, up from $13.2 million in the previous year. The company also saw a significant increase in data license revenue, which rose to $893,000 from $311,000, reflecting heightened commercial activity. However, other revenue streams, particularly from flow cytometry and the Lumin software-as-a-service offerings, experienced a decline as the company shifted its strategic focus.

Despite the increase in revenue, Champions Oncology reported a net loss of $426,000 for the quarter, slightly improved from a loss of $466,000 in the same period last year. The company's total operating expenses rose to $15.6 million, up from $14.5 million, largely due to increased sales and marketing expenses, which surged by 66.6% to $3.1 million as the company expanded its commercial organization. Research and development expenses also increased by 12.6% to $2.3 million, driven by higher stock-based compensation related to its subsidiary, Corellia.

Operationally, Champions Oncology's total assets increased to $33.3 million as of July 31, 2026, compared to $27.0 million at the end of April 2026. This growth was supported by an increase in cash and cash equivalents, which stood at $4.4 million, down from $4.9 million, and a rise in accounts receivable, which reached $13.6 million. The company’s liabilities also increased, totaling $28.8 million, up from $22.9 million, primarily due to higher operating lease liabilities following the expansion of its laboratory and office space.

Looking ahead, Champions Oncology expressed confidence in its ability to fund operations through at least September 2027, despite the net cash used in operations of $492,000 for the quarter. The company emphasized its commitment to enhancing its oncology services and expanding its data offerings, which are expected to drive future revenue growth. However, management acknowledged the potential need for additional capital to support ongoing research and development initiatives, although there is no assurance that such capital could be raised on favorable terms.